CORD-19:ceba28d8304f3df8001164f8edeef545154289f6 / 29929-30135 JSONTXT

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T104","span":{"begin":196,"end":199},"obj":"Disease"},{"id":"T44703","span":{"begin":196,"end":199},"obj":"Disease"}],"attributes":[{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0016318"},{"id":"A49459","pred":"mondo_id","subj":"T44703","obj":"http://purl.obolibrary.org/obo/MONDO_0016318"}],"text":"These findings have motivated efforts to isolate monoclonal antibodies capable of broadly cross-neutralizing wild type and VP1 mutant JCPyVs to protect patients at-risk of and as therapeutics for PML [54] ."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T172","span":{"begin":0,"end":206},"obj":"Sentence"},{"id":"TextSentencer_T172","span":{"begin":0,"end":206},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These findings have motivated efforts to isolate monoclonal antibodies capable of broadly cross-neutralizing wild type and VP1 mutant JCPyVs to protect patients at-risk of and as therapeutics for PML [54] ."}